IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v37y2019i1d10.1007_s40273-018-0699-1.html
   My bibliography  Save this article

Exploring Different Strategies of Assessing the Economic Impact of Multiple Diabetes-Associated Complications and Their Interactions: A Large Claims-Based Study in Germany

Author

Listed:
  • Katharina Kähm

    (Institute of Health Economics and Health Care Management, Helmholtz Zentrum München (GmbH)-German Research Center for Environmental Health (GmbH)
    German Center for Diabetes Research (DZD))

  • Michael Laxy

    (Institute of Health Economics and Health Care Management, Helmholtz Zentrum München (GmbH)-German Research Center for Environmental Health (GmbH)
    German Center for Diabetes Research (DZD))

  • Udo Schneider

    (Scientific Institute of TK for Benefit and Efficiency in Health Care, Techniker Krankenkasse (TK))

  • Rolf Holle

    (Institute of Health Economics and Health Care Management, Helmholtz Zentrum München (GmbH)-German Research Center for Environmental Health (GmbH)
    German Center for Diabetes Research (DZD))

Abstract

Background In the context of an aging population with increasing diabetes prevalence, people are living longer with diabetes, which leads to increased multimorbidity and economic burden. Objective The primary aim was to explore different strategies that address the economic impact of multiple type 2 diabetes-related complications and their interactions. Methods We used a generalized estimating equations approach based on nationwide statutory health insurance data from 316,220 patients with type 2 diabetes (baseline year 2012, 3 years of follow-up). We estimated annual total costs (in 2015 euros) for type 2 diabetes-related complications and, in addition, explored different strategies to assess diabetes-related multimorbidity: number of prevalent complications, co-occurrence of micro- and macrovascular complications, disease–disease interactions of prevalent complications, and interactions between prevalent/incident complications. Results The increased number of complications was significantly associated with higher total costs. Further assessment of interactions showed that macrovascular complications (e.g., chronic heart failure) and high-cost complications (e.g., end-stage renal disease, amputation) led to significant positive effects of interactions on costs, whereas early microvascular complications (e.g., retinopathy) caused negative interactions. The chronology of the onset of these complications turned out to have an additional impact on the interactions and their effect on total costs. Conclusions Health economic diabetes models and evaluations of interventions in patients with diabetes-related complications should pay more attention to the economic effect of specific disease interactions. Politically, our findings support the development of more integrated diabetes care programs that take better account of multimorbidity. Further observational studies are needed to elucidate the shared pathogenic mechanisms of diabetes complications.

Suggested Citation

  • Katharina Kähm & Michael Laxy & Udo Schneider & Rolf Holle, 2019. "Exploring Different Strategies of Assessing the Economic Impact of Multiple Diabetes-Associated Complications and Their Interactions: A Large Claims-Based Study in Germany," PharmacoEconomics, Springer, vol. 37(1), pages 63-74, January.
    • Handle: RePEc:spr:pharme:v:37:y:2019:i:1:d:10.1007_s40273-018-0699-1
    DOI: 10.1007/s40273-018-0699-1
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-018-0699-1
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-018-0699-1?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Kreis, Kristine & Neubauer, Sarah & Klora, Mike & Lange, Ansgar & Zeidler, Jan, 2016. "Status and perspectives of claims data analyses in Germany—A systematic review," Health Policy, Elsevier, vol. 120(2), pages 213-226.
    2. Alan Brennan & Stephen E. Chick & Ruth Davies, 2006. "A taxonomy of model structures for economic evaluation of health technologies," Health Economics, John Wiley & Sons, Ltd., vol. 15(12), pages 1295-1310, December.
    3. Maria Alva & Alastair Gray & Borislava Mihaylova & Philip Clarke, 2014. "The Effect Of Diabetes Complications On Health‐Related Quality Of Life: The Importance Of Longitudinal Data To Address Patient Heterogeneity," Health Economics, John Wiley & Sons, Ltd., vol. 23(4), pages 487-500, April.
    4. Borislava Mihaylova & Andrew Briggs & Anthony O'Hagan & Simon G. Thompson, 2011. "Review of statistical methods for analysing healthcare resources and costs," Health Economics, John Wiley & Sons, Ltd., vol. 20(8), pages 897-916, August.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Zhiyuan Hou & Ellen Van de Poel & Eddy Van Doorslaer & Baorong Yu & Qingyue Meng, 2014. "Effects Of Ncms On Access To Care And Financial Protection In China," Health Economics, John Wiley & Sons, Ltd., vol. 23(8), pages 917-934, August.
    2. Bernhard Ultsch & Oliver Damm & Philippe Beutels & Joke Bilcke & Bernd Brüggenjürgen & Andreas Gerber-Grote & Wolfgang Greiner & Germaine Hanquet & Raymond Hutubessy & Mark Jit & Mirjam Knol & Rüdiger, 2016. "Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community," PharmacoEconomics, Springer, vol. 34(3), pages 227-244, March.
    3. Becky Pennington & Alex Filby & Lesley Owen & Matthew Taylor, 2018. "Smoking Cessation: A Comparison of Two Model Structures," PharmacoEconomics, Springer, vol. 36(9), pages 1101-1112, September.
    4. Peter J. Dodd & Jeff J. Pennington & Liza Bronner Murrison & David W. Dowdy, 2018. "Simple Inclusion of Complex Diagnostic Algorithms in Infectious Disease Models for Economic Evaluation," Medical Decision Making, , vol. 38(8), pages 930-941, November.
    5. Tor Iversen & Eline Aas & Gunnar Rosenqvist & Unto Häkkinen & on behalf of the EuroHOPE study group, 2015. "Comparative Analysis of Treatment Costs in EUROHOPE," Health Economics, John Wiley & Sons, Ltd., vol. 24(S2), pages 5-22, December.
    6. Jonathan Karnon & James Stahl & Alan Brennan & J. Jaime Caro & Javier Mar & Jörgen Möller, 2012. "Modeling Using Discrete Event Simulation," Medical Decision Making, , vol. 32(5), pages 701-711, September.
    7. Jay Dev Dubey, 2021. "Measuring Income Elasticity of Healthcare-Seeking Behavior in India: A Conditional Quantile Regression Approach," Journal of Quantitative Economics, Springer;The Indian Econometric Society (TIES), vol. 19(4), pages 767-793, December.
    8. Kurt Lavetti & Thomas DeLeire & Nicolas R. Ziebarth, 2023. "How do low‐income enrollees in the Affordable Care Act marketplaces respond to cost‐sharing?," Journal of Risk & Insurance, The American Risk and Insurance Association, vol. 90(1), pages 155-183, March.
    9. Stuart J. Wright & William G. Newman & Katherine Payne, 2019. "Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review," PharmacoEconomics, Springer, vol. 37(8), pages 1011-1027, August.
    10. Arielle Anderer & Hamsa Bastani & John Silberholz, 2022. "Adaptive Clinical Trial Designs with Surrogates: When Should We Bother?," Management Science, INFORMS, vol. 68(3), pages 1982-2002, March.
    11. Eren Demir & David Southern, 2017. "Enabling better management of patients: discrete event simulation combined with the STAR approach," Journal of the Operational Research Society, Palgrave Macmillan;The OR Society, vol. 68(5), pages 577-590, May.
    12. Jen Kruger & Daniel Pollard & Hasan Basarir & Praveen Thokala & Debbie Cooke & Marie Clark & Rod Bond & Simon Heller & Alan Brennan, 2015. "Incorporating Psychological Predictors of Treatment Response into Health Economic Simulation Models," Medical Decision Making, , vol. 35(7), pages 872-887, October.
    13. Wameq A. Raza & Ellen van de Poel & Arjun Bedi & Frans Rutten, 2016. "Impact of Community‐based Health Insurance on Access and Financial Protection: Evidence from Three Randomized Control Trials in Rural India," Health Economics, John Wiley & Sons, Ltd., vol. 25(6), pages 675-687, June.
    14. Sarah Bates & Thomas Bayley & Paul Norman & Penny Breeze & Alan Brennan, 2020. "A Systematic Review of Methods to Predict Weight Trajectories in Health Economic Models of Behavioral Weight-Management Programs: The Potential Role of Psychosocial Factors," Medical Decision Making, , vol. 40(1), pages 90-105, January.
    15. F. Tomini & F. Prinzen & A. D. I. Asselt, 2016. "A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(9), pages 1159-1172, December.
    16. Eijkenaar, Frank & van Vliet, René C.J.A., 2017. "Improving risk equalization for individuals with persistently high costs: Experiences from the Netherlands," Health Policy, Elsevier, vol. 121(11), pages 1169-1176.
    17. Anikó Bíró & Péter Elek, 2018. "How does retirement affect healthcare expenditures? Evidence from a change in the retirement age," Health Economics, John Wiley & Sons, Ltd., vol. 27(5), pages 803-818, May.
    18. Penno, Erin & Sullivan, Trudy & Barson, Dave & Gauld, Robin, 2021. "Private choices, public costs: Evaluating cost-shifting between private and public health sectors in New Zealand," Health Policy, Elsevier, vol. 125(3), pages 406-414.
    19. Yu shin Park & Soo Young Kim & Eun-Cheol Park & Sung-In Jang, 2022. "Screening for Diabetes Complications during the COVID-19 Outbreak in South Korea," IJERPH, MDPI, vol. 19(9), pages 1-12, April.
    20. Luis Hernandez & Asli Ozen & Rodrigo DosSantos & Denis Getsios, 2016. "Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer’s Disease," PharmacoEconomics, Springer, vol. 34(7), pages 681-707, July.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:37:y:2019:i:1:d:10.1007_s40273-018-0699-1. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.